JP2017524021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524021A5 JP2017524021A5 JP2017509024A JP2017509024A JP2017524021A5 JP 2017524021 A5 JP2017524021 A5 JP 2017524021A5 JP 2017509024 A JP2017509024 A JP 2017509024A JP 2017509024 A JP2017509024 A JP 2017509024A JP 2017524021 A5 JP2017524021 A5 JP 2017524021A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- aripiprazole prodrug
- particles
- surface stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 16
- 229960004372 aripiprazole Drugs 0.000 claims 16
- 239000002245 particle Substances 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 16
- 239000000651 prodrug Substances 0.000 claims 16
- 239000003381 stabilizer Substances 0.000 claims 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims 4
- 238000000149 argon plasma sintering Methods 0.000 claims 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 4
- 229940068977 polysorbate 20 Drugs 0.000 claims 4
- 230000009977 dual effect Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000001509 sodium citrate Substances 0.000 claims 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 2
- 229940127236 atypical antipsychotics Drugs 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002612 dispersion medium Substances 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- -1 fatty acid esters Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000012064 sodium phosphate buffer Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000008215 water for injection Substances 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462038665P | 2014-08-18 | 2014-08-18 | |
| EP14181328.7 | 2014-08-18 | ||
| EP14181328 | 2014-08-18 | ||
| US62/038,665 | 2014-08-18 | ||
| PCT/EP2015/068872 WO2016026822A1 (en) | 2014-08-18 | 2015-08-17 | Aripiprazole prodrug compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019145176A Division JP6826167B2 (ja) | 2014-08-18 | 2019-08-07 | アリピプラゾールプロドラッグ組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524021A JP2017524021A (ja) | 2017-08-24 |
| JP2017524021A5 true JP2017524021A5 (cg-RX-API-DMAC10.html) | 2018-09-06 |
| JP6571166B2 JP6571166B2 (ja) | 2019-09-04 |
Family
ID=51352472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509024A Active JP6571166B2 (ja) | 2014-08-18 | 2015-08-17 | アリピプラゾールプロドラッグ組成物 |
Country Status (20)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| TR201905694T4 (tr) * | 2014-08-18 | 2019-05-21 | Alkermes Pharma Ireland Ltd | Aripiprazol ön ilaç bileşimleri. |
| SMT202100481T1 (it) | 2014-08-18 | 2021-09-14 | Alkermes Pharma Ireland Ltd | Composizioni per profarmaci di aripiprazolo |
| CA3014788A1 (en) | 2016-02-17 | 2017-08-24 | Alkermes Pharma Ireland Limited | Compositions of multiple aripiprazole prodrugs |
| CN110025572A (zh) * | 2018-01-11 | 2019-07-19 | 四川科伦药物研究院有限公司 | 月桂酰阿立哌唑混悬剂及其制备方法 |
| AU2019230014B2 (en) * | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN110327296B (zh) * | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
| WO2022260064A1 (ja) | 2021-06-08 | 2022-12-15 | 中外製薬株式会社 | ジヒドロピリダジン－３，５－ジオン誘導体を含有する製剤 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| ES2306452T3 (es) | 1995-10-17 | 2008-11-01 | Jagotec Ag | Aporte de farmacos insolubles. |
| GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
| JP2005508939A (ja) * | 2001-10-12 | 2005-04-07 | エラン ファーマ インターナショナル，リミティド | 即時放出および徐放特性を組み合わせて有する組成物 |
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| BRPI0415531B8 (pt) * | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| DE10350717A1 (de) * | 2003-10-30 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| EP1679065A1 (en) | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
| WO2007035348A2 (en) * | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| US20120238553A1 (en) | 2009-01-27 | 2012-09-20 | Neurosearch A/S | Novel benzodioxolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use |
| JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ |
| PT2445502T (pt) | 2009-06-25 | 2017-09-22 | Alkermes Pharma Ireland Ltd | Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos |
| CA3035442C (en) * | 2009-06-25 | 2022-07-19 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| ES2972387T3 (es) * | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| WO2013142202A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| CN103393594A (zh) * | 2013-08-22 | 2013-11-20 | 万特制药(海南)有限公司 | 一种新的阿立哌唑的制剂组合物 |
| AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| SMT202100481T1 (it) | 2014-08-18 | 2021-09-14 | Alkermes Pharma Ireland Ltd | Composizioni per profarmaci di aripiprazolo |
| SMT202100212T1 (it) | 2014-08-25 | 2021-07-12 | Alkermes Pharma Ireland Ltd | Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia |
| CN105012236A (zh) | 2015-08-10 | 2015-11-04 | 深圳市泛谷药业有限公司 | 一种长效非水载体注射液及其制备方法 |
-
2015
- 2015-08-17 SM SM20210481T patent/SMT202100481T1/it unknown
- 2015-08-17 EP EP19154013.7A patent/EP3508196B1/en active Active
- 2015-08-17 HR HRP20211271TT patent/HRP20211271T1/hr unknown
- 2015-08-17 PT PT191540137T patent/PT3508196T/pt unknown
- 2015-08-17 RS RS20190505A patent/RS58746B2/sr unknown
- 2015-08-17 JP JP2017509024A patent/JP6571166B2/ja active Active
- 2015-08-17 RS RS20210956A patent/RS62232B1/sr unknown
- 2015-08-17 CN CN202011416673.7A patent/CN112494492B/zh active Active
- 2015-08-17 MX MX2017002029A patent/MX371417B/es active IP Right Grant
- 2015-08-17 AU AU2015306198A patent/AU2015306198B2/en active Active
- 2015-08-17 CN CN201580055491.2A patent/CN106794251B/zh active Active
- 2015-08-17 PL PL19154013T patent/PL3508196T3/pl unknown
- 2015-08-17 SI SI201531670T patent/SI3508196T1/sl unknown
- 2015-08-17 SM SM20190236T patent/SMT201900236T1/it unknown
- 2015-08-17 EP EP15750750.0A patent/EP3182958B2/en active Active
- 2015-08-17 PL PL15750750.0T patent/PL3182958T5/pl unknown
- 2015-08-17 WO PCT/EP2015/068872 patent/WO2016026822A1/en not_active Ceased
- 2015-08-17 IL IL292079A patent/IL292079B2/en unknown
- 2015-08-17 HU HUE19154013A patent/HUE055711T2/hu unknown
- 2015-08-17 DK DK19154013.7T patent/DK3508196T3/da active
- 2015-08-17 ES ES19154013T patent/ES2884849T3/es active Active
- 2015-08-17 RU RU2017108204A patent/RU2705376C2/ru active
- 2015-08-17 BR BR112017002926A patent/BR112017002926A2/pt not_active Application Discontinuation
- 2015-08-17 CN CN202011448652.3A patent/CN112641785A/zh active Pending
- 2015-08-17 SI SI201530711T patent/SI3182958T2/sl unknown
-
2017
- 2017-02-14 IL IL250607A patent/IL250607B/en unknown
-
2021
- 2021-08-23 CY CY20211100753T patent/CY1124625T1/el unknown
- 2021-10-12 US US17/450,683 patent/US12642798B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202303593B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| CA2796755C (en) | Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative | |
| RU2020126034A (ru) | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции | |
| SG10201806300VA (en) | Liquid pharmaceutical composition | |
| JP2015514751A5 (cg-RX-API-DMAC10.html) | ||
| RU2017108204A (ru) | Композиции пролекарства арипипразола | |
| JP2016534153A5 (cg-RX-API-DMAC10.html) | ||
| HRP20191366T1 (hr) | Injekcijski pripravak | |
| JP2016510329A5 (cg-RX-API-DMAC10.html) | ||
| EA201592279A1 (ru) | Фармацевтическая композиция, ее получение и применение | |
| JP2016510765A5 (cg-RX-API-DMAC10.html) | ||
| JP2016516773A5 (cg-RX-API-DMAC10.html) | ||
| JP2015520241A5 (cg-RX-API-DMAC10.html) | ||
| EA201890703A1 (ru) | Коллоидные частицы, предназначенные для применения в медицине | |
| TW201828935A (zh) | 脂肪乳劑及其製造方法、使脂肪乳劑的安定性提升的方法、以及脂肪乳劑的安定性提升劑 | |
| JP2018503629A5 (cg-RX-API-DMAC10.html) | ||
| MX380536B (es) | Composicion y metodo para tratar la enfermedad de chagas. | |
| NZ767204B2 (en) | Aripiprazole prodrug compositions | |
| JP2015517534A5 (cg-RX-API-DMAC10.html) | ||
| HRP20190642T2 (hr) | Pripravci aripiprazolskog predlijeka | |
| EA032385B9 (ru) | Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта | |
| MX2022001330A (es) | Composicion oftalmica de bevacizumab. | |
| JP2015522608A5 (cg-RX-API-DMAC10.html) | ||
| RU2015104888A (ru) | Хиноксалиновые ингибиторы репликации вируса гепатита В и фармацевтическая композиция для лечения гепатита В | |
| Miranda-Bautista | Certolizumab pegol/corticosteroids |